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The therapeutic approach to advanced or metastatic solid tumors, either with chemotherapy or targeted therapies,
is mainly palliative. Resistance to chemotherapy occurs very frequently and is one of the most important reasons for
disease progression. Immunotherapy has the potential to mount an ongoing, dynamic immune response that can kill
tumor cells for an extended time after the conventional therapy has been administered. Such a long-lasting response is
potentially able to completely eradicate tumor cells, rather than producing only a temporary killing of cells. The most
promising immune-based treatments are monoclonal antibodies that act as checkpoint inhibitors (e.g. ipilimumab and
nivolumab), adoptive cell therapy (e.g. T-cells expressing chimeric antigen receptors) and vaccines (e.g. sipuleucel-T).
Ipilimumab is currently approved for the treatment of metastatic melanoma and sipuleucel-T is approved for advanced
prostate cancer. There is great interest in immunotherapy in other solid tumors, potentially used alone or in a multimodal
fashion with chemotherapy and/or biological drugs. In this paper, we review recent advances in immuno-oncology in
solid malignancies (except melanoma) as were discussed at the inaugural meeting of the Campania Society of Oncology
Immunotherapy (SCITO).
Keywords: Immunotherapy, Checkpoint inhibitors, Cellular vaccine, Antigen-specific vaccines, Solid tumorsIntroduction
The immune system is able to recognize and eradicate
cancer cells via multiple and complex mechanisms. Ehrlich
first proposed, in 1909, the idea that the immune system
could search and attack transformed cells before they are
clinically visible. Years later, this was confirmed by studies
involving tumor transplantation models that suggested the
existence of tumor-associated antigens and formed the
basis of immune surveillance [1].
The immune system can be divided into innate and adap-
tive. Innate immunity commonly refers to myeloid and
lymphoid cells that exert a rapid effector function, while
adaptive immunity is driven by T- and B-lymphocytes that
express antigen receptors produced by site-specific somatic* Correspondence: paolo.ascierto@gmail.com
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unless otherwise stated.recombination. Adoptive immunity has greater specificity
than innate in retaining antigen memory. The broadness
and quality of a T-cell response is regulated by a balance
of activating and inhibitory signals. In this scenario,
checkpoints are placed to limit an ongoing immune re-
sponse, thereby preventing damage to healthy tissues.
PD-1, CTLA-4, and LAG-3 are examples of inhibitory
checkpoints.
In human cancer, the immune system plays a double
role, both protecting against tumor development and pro-
moting tumor growth. This process is known as immu-
noediting and has three well-defined phases [2]. The
immunosurveillance (elimination) phase is characterized
by antigen presentation and T cell activation and, more
importantly, by destruction of nascent tumor cells and
control of tumor growth. In the equilibrium phase, the
main features are genetic instability and tumor heterogen-
eity, leading to a steady-state between tumor growth en-
hancement and inhibition. In the escape phase, cancerl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Summary of selected adverse events reported
with immune checkpoints inhibitors
Category Adverse events
Common
Skin Pruritus, rash, vitiligo, urticaria, alopecia, macular rash,
hypopigmentation, erytema, erytematous rash
Gastrointestinal Diarrhea, colitis, nausea, abdominal pain
Endocrine Hypothyroidism, hyperthyroidism, hypopituitarism,
hypophysitis, adrenal insufficiency, altered hormone levels
Hepatic Hepatitis, increased liver function enzymes
Pulmonary Pneumonitis, pulmonary edema
Uncommon
Ocular Uveitis, episcleritis, eye pruritus
Pancreatic Elevated lipase levels, hyperglycemia
Infusion-
related
Infusion-related reactions, hypersensitivity reactions
Hematologic Anemia, leukocytosis, thrombocytopenia
Neurologic Peripheral neuropathies, headache
General Fatigue, decreased appetite, arthralgia
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that can suppress or escape the immune system. T-
regulatory (T-reg) cells are crucially involved at this stage.
Tumor-infiltrating lymphocytes (TILs) have been identified
in many tumor types and often have prognostic value. The
presence of intratumoral T-cells strongly correlates with
improved clinical outcome in advanced ovarian carcinoma
[3] and in other solid tumors including non-small cell lung
(NSCLC) [4], colorectal [5], breast [6], head and neck [7]
and kidney cancer [8] as well as melanoma [9]. Conversely,
T-reg infiltration has been reported to predict a poorer out-
come in early-stage NSCLC [10], in melanoma [11], and in
renal cell carcinoma [12].
Checkpoint blockade: now a reality?
The two main inhibitory checkpoint pathways involve
signaling through CTLA-4 or PD-1. Both systems are
crucial in promoting tumor growth and proliferation:
CTLA-4 is competitive for the costimulatory binding
CD80/86-CD28 and its binding to CD80/86 generates a
negative signal which is responsible for immune cell in-
activation. PD-1 binding to PD-L1 and PD-L2 molecules
also generates a negative and inhibitory signal respon-
sible for immune escape. The CTLA-4 pathway is more
important in the early phase of the immune system acti-
vation (priming phase), while the PD-1 pathway is more
important in the tumor microenvironment during the
effector phase [13,14]. Inhibition of CTLA-4 and PD-1
binding to their ligands enhances T-cell activation and
proliferation, leading to tumor infiltration by T-cells and
tumor regression.
The anti-CTLA-4 monoclonal antibody (moAb) ipili-
mumab was the first therapy to improve overall survival
(OS) in a phase III trial in patients with metastatic melan-
oma, when compared with GP100, a peptide vaccine [15].
Progression-free survival (PFS) and best overall response
rate (BORR) also favored patients receiving ipilimumab,
alone or in combination with GP100, as compared with the
vaccine alone. Most adverse events (AEs) reported with ipi-
limumab were immune-related (irAEs) and were managed
with specific algorithms [16]. The most frequently reported
irAEs in the ipilimumab arm were diarrhea (28%), pruritus
(24%) and rash (19%).
When the PD-1 receptor binds with its ligand (PD-L1/
B7-H1), which is frequently overexpressed on tumor cell
surfaces, T-cell inhibition and down-regulation of T-cell
responses occurs. This allows tumors to directly halt anti-
tumor T-cell activity, also known as adaptive resistance.
Blocking PD-1 or PD-L1 through the use of therapeutic
moAbs empowers the T-cell response. Promising long-
term survival results have been achieved with the anti-
PD1 moAb nivolumab. In a phase I trial in patients with
advanced solid tumors, nivolumab was associated with a
2-year survival rate of 24% in NSCLC, 43% in melanoma,and 50% in renal cell carcinoma [17-19]. Patients treated
with 3 mg/kg or 10 mg/kg had an objective response rate
(ORR) greater than those treated with 1 mg/kg (24% and
20% versus 3%). Grade 3–4 AEs were reported in 17% of
patients, mainly rash, diarrhea and pruritus. The nivolu-
mab 3 mg/kg dose reached a median OS of 14.9 months
and was selected for future registration trials.
Immune checkpoints inhibitors have different toxicity
profiles compared to chemotherapy or targeted therapies
(Table 1). Some AEs have different etiologies compared
with those related to chemotherapy (e.g. diarrhea, rash)
and require different management. These irAEs result
from increased activity of the immune system, can
involve multiple organs and may be severe or life-
threatening. In such cases, systemic high-dose cortico-
steroids may be required. Patient education is essential
in order to early recognize irAEs and to minimize life-
threatening complications.
Predictive biomarkers for immuno-oncology therapies,
to be correlated with efficacy and toxicity, are under in-
vestigation. However, due to their being directed against
the patient’s immune system rather than the tumor, a
different approach for identifying biomarkers in this field
may be needed [20]. A promising approach could be the
expression of biomarkers related to the target pathway.
For example, PD-L1 seems an effective biomarker for
therapies directed against the PD-1 pathway, such as
nivolumab and pembrolizumab. Some studies in NSCLC
and melanoma showed that the ORR in patients with
PD-L1 positivity were higher when compared withPD-L1
negative patients (Table 2) [17,21,22]. However, key
questions remain over variability in tissue collection
Table 2 PD-L1 as a potential efficacy biomarker: response
according to PD-L1 expression in NSCLC and melanoma
Tumor PDL-1 + ve PDL-1-ve
ORR n/N (%) ORR n/N (%)
MPDL3280A
Hamid et al. ASCO #9010
Melanoma 4/15 (27%) 3/15 (20%)
Nivolumab
Weber et al. ASCO #9011
Melanoma 8/12 (67%) 6/32 (19%)
Nivolumab
Grosso et al. ASCO #3016
Melanoma 7/16 (44%) 3/18 (17%)
Nivolumab
Topalian et al. NEJM 2012
Melanoma 9/25 (36%) 0/17 (0%)
Nivolumab
Antonia et al. WCLC 2013
NSCLC 5/31 (16%) 4/32 (13%)
Pembrolizumab
Garon et al. WCLC 2013
NSCLC 4/7 (57%) 2/22 (9%)
MPDL3280A
Horn et al. WCLC2013
NSCLC 8/26 (31%) 4/20 (20%)
Nivolumab/ipilimumab
Callahan et al. ASCO#3003
Melanoma 4/10 (40%) 8/17 (47%)
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chemical (IHC) criteria to determine a significant cut-off
between wild-type and mutation status.
In order to maximise clinical benefit, multiple sequen-
tial or combination approaches between immunother-
apy, chemotherapy, radiotherapy and targeted drugs are
under investigation. Clinical trials combining immuno-
oncology therapies that modulate different pathways or
target distinct and potentially complementary immune
pathways (e.g. anti-PD-1 plus anti-CTLA-4 or anti-LAG3
antibodies) are ongoing in advanced solid tumors. The
synergistic activity between immuno-oncology therapies
and chemotherapy has also been extensively demonstrated
both in vitro and in vivo. For example, ipilimumab in
combination with dacarbazine (DTIC) showed a long-
term survival benefit compared with placebo plus DTIC
in patients with metastatic melanoma [23].
The need for new endpoints in immuno-oncology
The value and the meaning of endpoints in the develop-
ment of new anticancer drugs has been a topic of keen
interest in recent years. Targeted drugs can interfere with
tumor cell growth in a substantially different manner to
cytotoxic drugs. Thus, the need to observe tumor shrinkage
in order to consider a drug active has been questioned. In-
deed, with such drugs, it was anticipated that slowing the
growth of tumor cells might be clinically meaningful even
in the absence of significant tumor shrinkage. Drugs inter-
fering with the immune system pose other different prob-
lems, in that stimulation of immunocompetent cells may
produce an infiltration of tumor masses that tend to in-
crease the volume of the lesion, thereby counterbalancing
the reduction in tumor cells. Such phenomenon translatesinto the need to review objective response (OR) criteria, be-
cause common RECIST and WHO criteria might not be
adequately sensitive.
Phase I studies in melanoma clearly illustrate that an
initial increase in tumor volume or the appearance of new
lesions does not necessarily mean therapeutic failure [24]
and that stable disease (SD) may be an indicator of a clin-
ically meaningful therapeutic effect. In a nivolumab phase
I trial, it was shown that ORs may occur early or late and
may also continue after drug discontinuation [17]. Among
responders who stopped treatment for reasons other than
progressive disease (PD) (n = 27), 70% maintained the
response off-drug for 16 to 59 weeks.
Anti-CTLA-4 and anti-PD1 moAbs may act regard-
less of patient characteristics (age, gender, ECOG PS)
and disease characteristics (histology, mutation status,
type of prior therapies). This was observed with nivolu-
mab in NSCLC [25] and ipilimumab in melanoma [26].
In the Italian extended-access programme (EAP), ipili-
mumab was shown to be active irrespective of muta-
tional status: disease control rates (DCR) and OS were
comparable between BRAF or NRAS-mutated and wild-
type patients in a very large population [27] (Figures 1
and 2). Across the phase II-III clinical trial program,
four patterns of response to ipilimumab in patients with
advanced melanoma were observed and named as
immuno-related response criteria (irRC): (1) response in
baseline lesions; (2) SD with slow, steady decline in total
tumor volume; (3) response after initial increase in total
tumor volume; (4) reduction in total tumor burden after
the appearance of new lesions [28]. In the CA184-008
and CA184-022 trials of ipilimumab in metastatic mel-
anoma, the tumor responses of 167 evaluable patients
have been assessed with the irRC [29,30]. Twenty-two
patients were characterized as having an immuno-
related partial response (PR) (n = 5) or irSD (n = 17),
who otherwise would be labelled as PD by conventional
WHO criteria.
Such considerations imply that tumor assessments should
be performed only after completion of the assigned regimen
and the results confirmed with a follow-up scan [28]. With
drugs such as ipilimumab, the planned treatment should be
administered regardless of the early appearance of new
lesions or volume increase of existing lesions, as immune
cell infiltration following immunotherapy may mimic
tumor progression. Data from clinical trials and ipilimumab
EAPs indicate that long-lasting SD is a common outcome
with immunotherapy and that, even with no evidence of a
tumor response, durable disease control can result in pro-
longed OS [31]. Such evidence clearly suggests that classical
response rates (RR) and PFS cannot be considered as valid
surrogate of OS or long-term clinical benefit. Before defini-
tive trials that address OS as end-point are available, other





























Figure 1 Ipilimumab clinical activity (OS) irrespective of BRAF mutational status: the Italian EAP in melanoma by Ascierto et al. J Trans
Med 2014; 12: 116–122 [26].
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more predictive of survival duration [32].
Immunotherapy of solid tumors
Lung cancer
Lung cancer has historically been considered as a non-
immunogenic cancer, so immunotherapy has not been
extensively studied in this field. However, more recently,
advances in the understanding of antitumor immune eva-
sion and response mechanisms have led to preliminary
positive results with different immuno-oncology strategies
in NSCLC. The first evidence of efficacy with a moAb in
combination with chemotherapy in advanced NSCLC has
been obtained with ipilimumab in a randomized phase II
trial [33]. Treatment-naïve patients with stage IIIB/IV
NSCLC were randomized to receive standard chemother-
apy (carboplatin plus paclitaxel q3w) in combination with
placebo or ipilimumab in one of the following regimens:
















Figure 2 Ipilimumab clinical activity (OS) irrespective of NRAS mutati
Med 2014; 12: 116–122 [26].carboplatin followed by two doses of placebo plus pacli-
taxel and carboplatin) or phased (two doses of placebo
plus paclitaxel and carboplatin followed by four doses of
ipilimumab plus paclitaxel and carboplatin). Maintenance
therapy with placebo or ipilimumab was administered for
12 weeks following the induction phase. The study met its
primary endpoint of improved irPFS versus the control
arm but only for phased ipilimumab (HR 0.72; p = 0.05)
and not for the concurrent arm (HR 0.81). Improvement
in irPFS was greater in patients with squamous histology
(HR 0.55). Another randomized phase II trial, with the
same design and treatment arms, enrolled patients with
advanced small-cell lung cancer (SCLC), confirming the
benefit in irPFS of ipilimumab plus chemotherapy versus
chemotherapy alone [34]. However, both trials failed to
show any significant OS difference between the arms,
probably due to being underpowered for this endpoint.
Currently, there are two ongoing multicenter, randomized,
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in patients with SCLC and squamous NSCLC. Tremeli-
mumab, another anti-CTLA4 moAb, has also been stud-
ied in the maintenance setting for NSCLC patients with
stable or responding disease after first-line chemotherapy,
showing no improvement in PFS as compared with best
supportive care (BSC) [35].
PD-1 inhibitors, such as nivolumab or pembrolizumab,
are potentially active in NSCLC because PD-1 receptors
are highly expressed on NSCLC infiltrating T-cells.
CA209-003/CHECKMATE-003 is a phase I trial assessing
the safety, antitumor activity, pharmacodynamics and
pharmacokinetics of nivolumab in patients with advanced
solid tumors, including NSCLC [18]. The NSCLC cohort
(n = 129) has been randomised to receive three nivolumab
dose levels: 1, 3 or 10 mg/kg q3w. More than 50% of
patients were heavily pretreated, receiving at least three
lines of therapy for advanced disease. ORR was 17% across
doses (24% with nivolumab 3 mg/kg), with no significant
difference across histology types (16.7% for squamous and
17.6% for non-squamous). Responses were durable,
occurred early (50% at first assessment at 8 weeks) and
were maintained after treatment discontinuation. Thirty-
eight percent of responders who discontinued therapy for
reasons other than PD responded for ≥30 weeks following
end of therapy. Patients with PD-L1 overexpression
(at least 5% of tumor membrane PD-L1 staining) seemed
to have the best change in target lesion tumor burden.
However, an exploratory analysis did not show any advan-
tage in survival in the group of patients who overex-
pressed PD-L1 as compared with patients who did not.
The 3 mg/kg q3w nivolumab dose obtained a median OS
of 14.9 months, with 1- and 2-year OS rates of 56% and
45%, respectively, with no difference across histology.
Interim results of a first-line nivolumab monotherapy
study in advanced NSCLC were also presented at ASCO
2014 [25]. Patients with chemotherapy-naïve NSCLC
reported a 30% ORR, with two patients achieving a con-
firmed complete response (CR) and another one uncon-
firmed. More than 2/3 of responses were ongoing at the
time of analysis. Tumor PD-L1 expression status seems to
be related with response: ORR was 50% in PD-L1-positive
patients, with no responses reported in PD-L1-negative
patients. Nivolumab monotherapy had a tolerable safety
profile, with a low frequency of grade 3/4 treatment-related
AEs and no treatment-related deaths.
PD-1 and CTLA-4 are non-overlapping immune check-
points in T-cell differentiation and have demonstrated anti-
tumor synergy in murine models and melanoma patients.
A combination phase I study of nivolumab and ipilimumab
in patients with previously untreated advanced NSCLC is
ongoing, and preliminary results (n = 49) were recently
presented [36]. Two different doses of nivolumab and ipi-
limumab (1 mg/kg and 3 mg/kg q3w) were combined inthis trial, and subsequent nivolumab-only maintenance
(3 mg/kg q3w) was offered until disease progression or
toxicity. Nivolumab in combination with ipilimumab pro-
vided durable ORR regardless of histology. Activity was
shown irrespective of tumor PD-L1 status, suggesting that
the combination may be suitable for both PD-L1-negative
and PD-L1-positive patients. There was no clear relation-
ship between efficacy outcomes (ORR, PFS and OS) and
PD-L1 status, as previously reported in patients with
melanoma.
Nivolumab in combination with standard platinum-
based chemotherapy as front-line treatment in advanced
NSCLC has also been explored in a phase I trial [37].
Preliminary results showed that antitumor activity of
nivolumab added to chemotherapy was similar to that
previously reported for standard platinum-based doublet
regimens. ORR ranged from 33–47% across treatment
arms, with OS and PFS data consistent with those previ-
ously reported in patients treated with chemotherapy
alone. These results also revealed a safety profile reflect-
ing additive toxicities of nivolumab and chemotherapy,
although with no higher frequency of severe grade AEs.
In patients with EGFR-mutant non-squamous NSCLC,
the combination of nivolumab plus erlotinib has shown
an encouraging and durable response rate, with a man-
ageable safety profile [38].
Vaccines are potentially effective in patients with lung
cancer. Maximal benefit could be attained in patients
with minimal disease, such as after resection, definitive
chemo-radiation and PR or CR on first-line combination
therapy. Some interesting results have been obtained in
NSCLC with tumor cell-derived multiple and specific
antigen vaccines. Belagenpumatucel-L (Lucanix) is an
allogeneic tumor cell vaccine made with four irradiated
NSCLC cell lines and modified with transforming
growth factor-β2 (TGF-β2) antisense plasmid, which im-
proves the immune response. In a phase III, placebo-
controlled trial in patients with stage III/IV NSCLC and
disease control after first-line chemo-radiotherapy (CT-
RT), Lucanix was administered as monthly intradermal
injections for 18 months, followed by two injections on
a quarterly basis [39]. This trial did not meet its primary
endpoint (OS), but a significantly prolonged survival was
shown in patients who began the vaccine within
12 weeks from the completion of front-line treatment,
both in squamous and non-squamous histology.
Melanoma-associated antigen A3 (MAGE-A3) is a
tumor specific antigen that is aberrantly expressed in
approximately 35% of NSCLC and is not expressed on
non-malignant cells, except for testicular germ cells and
placental trophoblasts. MAGE-A3 vaccine is composed of
the MAGE-A3 protein plus an adjuvant AS15. In a phase
II randomized study, patients with resected NSCLC were
randomly assigned to either MAGE-A3 (n = 122) or
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of 44 months, recurrence was observed in 35% of patients
in the MAGE-A3 arm and 43% in the placebo arm. No
statistically significant improvement in disease-free inter-
val (DFI)(HR 0.75, p = 0.254), disease-free survival (DFS)
(HR, 0.76; p = 0.248) or OS (HR, 0.81; p = 0.454) was ob-
served. A similar trend for DFI and DFS was revealed after
a longer follow-up period (70 months). Moreover, a large
randomized phase III trial with adjuvant MAGE-A3 vac-
cine after adjuvant chemotherapy in patients with resected
stage IB through IIIA MAGE-A3 positive NSCLC failed to
meet its primary endpoint [41].
Liposomal BLP-25 (L-BLP-25, Tecemotide) is a peptide-
based vaccine targeting the exposed core peptide of
membrane-associated glycoprotein (MUC-1), normally
expressed on epithelial cells. Tumor-associated MUC-1,
which is aberrantly glycosylated, is antigenically distinct
from normal MUC-1 and it is associated with oncogenesis
and resistance to chemotherapy. MUC-1 is overexpressed
in approximately 60% of lung cancers. In a randomized
phase IIB study, patients with stable or responding stage
IIIB or IV NSCLC after first-line chemotherapy received L-
BLP-25 plus BSC or BSC alone [42]. Patients in the vaccine
arm received a single intravenous dose of cyclophospha-
mide 300 mg/m2 followed by eight weekly subcutaneous
immunizations with L-BLP-25 (1000 μg). Subsequent im-
munizations were administered at 6-week intervals. The
median survival time was 4.4 months longer (non-statisti-
cally significant) for patients assigned to the L-BLP-25 arm
(n = 88) as compared to patients in the BSC arm (n = 83),
with an adjusted hazard ratio of 0.739. The greatest effect
was observed in stage IIIB patients, where the median sur-
vival time for the vaccine arm has not yet been reached
compared with 13.3 months for the BSC arm.
A subsequent randomized phase III trial with tecemo-
tide in patients with stage III NSCLC who received con-
current or sequential CT-RT reported no significant
difference in OS with tecemotide compared with placebo
in the intention-to-treat population [43]. In the subgroup
of patients who received concurrent CT-RT, median OS
for patients assigned to the experimental arm was
30.8 months (95% CI 25 · 6–36 · 8) as compared with
20.6 months (17 · 4–23 · 9) for those who received placebo
(adjusted HR 0 · 78, 0 · 64–0 · 95; p = 0 · 016). Possible rea-
sons for improved results with concurrent CT-RT could
be the better performance status and the smaller tumor
size in patients who received this treatment. Some authors
recently postulated that the favorable outcome of concur-
rent CT-RT in different solid tumors might be explained
by immunogenic cell death [44]. The activity of other
promising vaccines in NSCLC, such as MUC-1 antigen-
derived TG 4010 and EGF-derived CIMAvax, has been
shown in phase II trials [45,46]. Survival results from
phase III trials are awaited, as well as further investigationsto identify patient subgroups that might benefit from these
strategies.
Colorectal cancer
Although it is known that tumor-specific T-cells can be
isolated from patients with gastrointestinal (GI) tumors,
the potential use of immunotherapy to treat advanced
GI malignancies is far from realization. Infiltration of T-
cells into GI tumors correlates with improved prognosis,
while the presence of negative regulatory factors that in-
hibit antitumor T-cell responses correlates with a poor
prognosis [47].
PD-L1 expression seems to correlate with decreased
immune activation and poor clinical outcome in GI tu-
mors. Expression of PD-L1 in colorectal cancer occurs
in about 60% of patients [48]. However, a phase I study
of nivolumab for advanced or recurrent colorectal can-
cer reported limited activity [17].
Patients with high levels of microsatellite instability
could potentially have greater benefit from immunother-
apies in metastatic colorectal cancer. In this group of pa-
tients, a clinical phase I/II trial exploring the feasibility
of nivolumab plus ipilimumab combination is ongoing
(http://clinicaltrials.gov/ct2/show/NCT02060188). Apart
from moAbs, other promising immune-therapy strategies
are emerging in colorectal cancer, such as vaccination and
adoptive cell therapies.
Gastrointestinal (non-colorectal) cancer
Monotherapy with ipilimumab was shown to be ineffect-
ive in patients with advanced pancreatic cancer unsuitable
for surgery in a single-arm phase II trial that enrolled 27
patients (20 with stage IV disease) [49]. Symptoms related
to disease progression limited the number of doses re-
ceived by patients, with only 12 receiving at least one
course. There were no responders by RECIST criteria,
with only one patient who experienced a delayed response.
Although ipilimumab was ineffective, the significant de-
layed response in one patient suggests that immunothera-
peutic approaches deserves further exploration in this
field.
A randomized, open-label phase II trial comparing ipi-
limumab versus BSC after platinum and fluoropyrimidine-
based doublet first-line chemotherapy in unresectable or
locally advanced/metastatic gastric cancer is ongoing
(http://www.clinicaltrials.gov/ct2/show/NCT01585987).
Primary endpoint is to achieve an irPFS benefit from
ipilimumab as compared to BSC in patients who did not
progress after first-line chemotherapy.
In patients with hepatocellular carcinoma (HCC) not
suitable for local treatment strategies, survival data are very
poor. Sorafenib remains standard therapy in patients with
an acceptable hepatic function (usually characterized as
Child class A or B). This first-generation tyrosine-kinase
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in time to progression (TTP) and OS compared with pla-
cebo, both in Caucasian and Asian patients [50,51]. From a
biological point of view, HCC seems to be a very complex
disease, involving multiple pathways which could be tar-
geted in order to improve outcomes. Despite this, random-
ized phase III trials comparing targeted therapies versus
sorafenib have dramatically failed in the first-line setting
[52,53]. Very poor results have also been obtained with
second-line therapy in two phase III trials that compared
everolimus or brivanib to placebo (Table 3) [53].
Other interesting trials are ongoing in GI non-colorectal
malignancies. PD-L1 expression accounts for about 40% of
patients both in esophageal/gastric and pancreatic cancers
[48] and trials have been designed to evaluate the activity
and toxicity of anti-CTLA-4 in combination with anti-PD-
1/PD-L1 drugs in patients with GI non-colorectal tumors.
CA 209–032 is a phase I/II open-label study of nivolumab
alone or combined with ipilimumab in patients with ad-
vanced solid tumors including gastric and pancreatic cancer
(http://www.clinicaltrials.gov/ct2/show/NCT01928394). In
the experimental arm, nivolumab is administered at
1 mg/kg or 3 mg/kg q2w in combination with standard ipi-
limumab dose and schedule (four doses at 3 mg/kg q3w).
Tremelimumab is being evaluated in an ongoing phase II
trial; accrual has completed and results are awaited. Pidili-
zumab is an anti-PD-L1 antibody which is able to reduce
T-lymphocyte apoptosis and enhance natural-killer cell ac-
tivity. A phase I/II trial in patients with solid tumors is
ongoing.
Central nervous system tumors
Glioblastoma multiforme (GBM) is the most frequent pri-
mary tumor of the central nervous system (CNS) inTable 3 Summary of phase III trial (first- and second-line) in a
Treatment Principal targets
First-line
Sunitinib vs SOR VEGFR, PDGFRa/b, c-KIT, FL
Cheng et al. 2013
Brivanib vs SOR (BRISK-FL) VEGFR, FGFR
Johnson et al. 2013
Linifanib vs SOR VEGFR, PDGFR
Cainap et al. 2012
Erlotinib/SOR vs placebo/SOR (SEARCH) EGFR
Zhu et al. 2012
Second-line
Brivanib vs BSC (BRISK-APS) VEGFR, FGFR
Llovet et al. 2013
Everolimus vs BSC (EVOLVE-1) mTOR
Zhu et al. 2014
BSC = best supportive care, HR = hazard ratio, SOR = sorafenib.adults. Despite a multimodal therapeutic approach involv-
ing surgery, radiotherapy and temozolomide-based
chemotherapy, median survival does not extend beyond
around 15 months. Moreover, these therapies damage
normal tissue and there is a need for more specific and ef-
fective treatment that is able to selectively target tumor
cells without damaging normal brain tissue. CNS has to
be considered as an immunologically privileged site with
the blood–brain barrier (BBB) of the cerebrovascular
endothelium reducing entry of immune cells and immune
mediators to the CNS. Nevertheless, despite the absence
of lymphatic vessels and nodes, in pathological conditions
a very well organized immunological response can develop
within the CNS. Bevacizumab, an anti-VEGF MoAb, has
shown activity in patients with recurrent GBM and has
obtained regulatory approval for clinical use in the US
[54,55]. Nevertheless, bevacizumab failed to improve sur-
vival outcomes when combined with temozolomide plus
RT as front-line treatment in two large clinical trials
[56,57].
Anti-EGFR targeted therapy seems to be a promising
approach in malignant gliomas. EGFR variant III (EGFR
vIII) is one of the most frequent mutations in GBM (about
40% of total) [58]. Variant III is a deletion in the 267 pos-
ition of the EGFR extracellular domain, not expressed in
normal glioma tissue but only in glioblastoma cells. The
most promising peptide vaccine targeting EGFR vIII is rin-
dopepimut (CDX-110), which contains a peptide derived
from the novel fusion junction amino acid sequence of
EGFR vIII. Rindopepimut is able to activate humoral and
cellular immunoreactivity, and has been shown to induce
EGFR vIII-specific immune responses in preclinical and
clinical studies [59]. A phase II, multicenter trial was con-
ducted to assess the immunogenicity of rindopepimut anddvanced hepatocellular carcinoma
Patients (n) Median overall survival
T3, RET 1074 8.1 vs 10 months
HR 1.31 (1.13-1.52), p = 0.0019)
1155 9.5 vs 9.9 months
HR 1.07 (0.94-1.23), p = 0.3116
1035 9.1 vs 9.8 months
HR 1.046 (0.896-1.221), p = 0.1785
720 9.5 vs 8.5 months
HR 0.929 (0.781-1.106), p = 0.204
395 9.4 vs 8.2 months
HR 0.89 (0.69-1.15), p = 0.3307
546 7.6 vs 7.3 months
HR 1.05 (0.86-1.27), p = 0.675
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newly diagnosed EGFR vIII-positive GBM with minimal
residual disease [60]. PFS was 14.7 months in the vaccine
group (n = 18) and 6.3 months in the historical control
group who received temozolomide (n = 17). Median OS
was 26.0 months in the vaccine group and 15.0 months in
the control group. Based on these promising results, a
phase II study of the safety and efficacy of rindopepimut
in combination with bevacizumab is ongoing (ReACT
study). Patients with GBM and EGFR vIII mutation who
relapse after RT plus temozolomide are randomized to
receive bevacizumab plus rindopepimut or keyhole limpet
hemocyanin as a control. As bevacizumab blocks VEGF
and has immunosuppressive properties, the hypothesis is
that the combination could enhance the immunogenic
response of rindopepimut against EGFR vIII-expressing
GBM cells.
Gynecologic cancers
The immune system plays an active role in the pathogen-
esis of ovarian cancer, as well as in the mechanisms of dis-
ease progression and OS. Immunotherapy in gynecological
cancers could help to revert immunosuppression and
lymphocyte depletion due to locoregional and systemic
treatments. CD4+ T-reg cells rapidly decrease after primary
tumor debulking in patients with ovarian cancer. Similar
results could also be obtained in patients “chemically
debulked” with neoadjuvant chemotherapy [61]. Active im-
munotherapy with antigen-specific peptide vaccination is
one of the most promising strategies in gynecological can-
cers. NY-ESO-1 is one of the most immunogenic tumor
antigens and is frequently expressed both in ovarian and in
vulvar cancers. Immunization with peptide epitope ESO
(157–170) in patients with ovarian cancer (minimal disease)
enhances the production of CD4+ and CD8+ cell clones.
These cells are able to recognize NY-ESO-1 expressing
tumor targets and were detectable up to 12 months after
immunization [62].
Abagovomab (ACA 125) is an anti-idiotypic moAb that
functionally imitates the tumor antigen CA 125, overex-
pressed in patients with gynecological cancers. Abagovo-
mab is able to induce a specific anti-anti-idiotypic antibody
response in about 70% of patients with advanced ovarian
cancers. A median survival of 23.4 months has been
observed in the group of patients with an antibody re-
sponse, compared with only 5 months in patients without
[63]. In a randomized multicenter phase III trial, patients
with stage III-IV ovarian cancer in complete remission
after primary surgery and platinum- and taxane-based
chemotherapy were assigned to receive maintenance ther-
apy with abagovomab or placebo [64]. Abagovomab was
safe and induced a measurable immune response. How-
ever, no significant benefit in relapse-free survival and OS
was obtained compared with placebo. Comparable resultshave been obtained by oregovomab, another CA-125-
specific murine moAb, after front-line therapy in a favor-
able subset of patients with ovarian cancer [65].
The multifunctional antibody catumaxomab binds both
to the EpCAM tumor cell antigen and to CD3+ lympho-
cytes, enhancing antitumor activity by redirecting T-cells
and Fcgamma receptor I/III-positive accessory cells to the
tumor. A phase II dose-escalation study investigated toler-
ability and efficacy in patients with ovarian cancer-induced
malignant ascites [66]. Treatment with catumaxomab
resulted in significant and sustained reduction of ascites
flow rate, with more than 90% of patients not requiring
paracentesis between the last infusion and the end of study.
Tumor cell monitoring also revealed a reduction of
EpCAM-positive malignant cells in ascites by up to 5 log. A
subsequent phase III randomized, placebo-controlled trial
revealed that tumor cell numbers and peritoneal levels of
VEGF decreased with catumaxomab, whereas the activation
status of CD8+ and CD4+ T-cell populations increased
more than two-fold after treatment [67].
Interleukins have been extensively studied as a poten-
tial treatment strategy in advanced ovarian cancer.
Human-recombinant IL-12 (rhIL-12) has an anti-
angiogenic effect and, when administered intraperitone-
ally, enhances tumor response across local delivery of
other cytokines. A phase II multicenter trial has investi-
gated the efficacy and toxicity profile of rhIL-12 in pa-
tients with advanced ovarian cancer and peritoneal
carcinomatosis (residual disease <1 cm) after primary
therapy [68]. Intraperitoneal IL-12 seems to have a good
toxicity profile, but only achieved SD and no responses
in this group of patients. Cytokine response profiles
suggest either NK or T-cell mediated effects of IL-12. A
pleiotropic immunologic response was induced by rhIL-
12, with both anti-tumor (driven by IFN-gamma, IP-10)
and pro-tumor growth effects (VEGF, IL-8).
The tumor microenvironment can modify dendritic cell
function in an immunosuppressive fashion, with strong in-
hibition of dendritic cell activation and maturation [69].
Dendritic cell vaccines redirect T-cell immunity from
immune-suppression to pro-inflammatory anti-tumor
responses. Encouraging results obtained in small studies
with some PRs achieved [70,71] mean that dendritic cell
vaccine strategies should be assessed in larger clinical
trials. Patient populations should have minimal disease at
the time of vaccination, and should preferably have com-
pleted surgery and chemotherapy. The goal is to prevent
disease recurrence or progression, rather than use den-
dritic cell vaccination as salvage therapy in women with
significant tumor burden.
Promising data with anti-PD-1 therapy in patients with
platinum-resistant ovarian cancer have recently been
presented [72]. Patients with recurrent or refractory dis-
ease (n = 20) received nivolumab at 1 mg/kg or 3 mg/kg
Figure 3 OS improvement in the treatment of advanced mHNC
adding anti-EGFR MoAbs to chemotherapy [74,76].
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Standard chemotherapy was concurrently administered
every 8 weeks during the study. Combination therapy
was well tolerated, with few treatment-related severe
AEs. A total ORR of 17% was obtained. The 3 mg/kg co-
hort seemed to have the most favourable outcome, with
25% RR and 63% DCR. Biomarkers predicting response
or AEs are being explored in this trial.
Head and neck cancers
The prognosis of patients with recurrent or metastatic head
and neck cancer (mHNC) is very poor with median survival
ranging from 6 to 9 months depending upon patient- and
disease-related factors. EGFR is strongly overexpressed in
the majority (80-100%) of patients with squamous cell
carcinoma of the head and neck [73]. The EGFR-directed
moAbs cetuximab and panitumumab are the mainstay of
treatment combined with standard chemotherapy in
patients with recurrent disease. In the EXTREME study,
442 patients with mHNC were randomized to receive
platinum-based chemotherapy (cisplatin or carboplatin)
plus 5-fluorouracil every three weeks to a maximum of six
cycles, with or without weekly cetuximab [74]. Patients in
the cetuximab arm had the option to continue anti-EGFR
as maintenance treatment until disease progression or
unacceptable toxicity. The addition of cetuximab to chemo-
therapy significantly improved median OS (primary end-
point) from 7.4 to 10.1 months (HR 0.80, 95% CI, 0.64–
0.99). Median PFS also increased from 3.3 to 5.6 months
(HR 0.54, 95% CI 0.43–0.67), and RR improved from 20%
to 36%. Treatment with cetuximab was well tolerated. A
retrospective biomarker analysis of this trial revealed that
there was no predictive correlation between gene copy
number and cetuximab efficacy [75].
The SPECTRUM trial randomized 657 patients with
mHNC to receive cisplatin + 5-fluorouracil ± panitumu-
mab [76]. The addition of panitumumab significantly
improved median PFS (5.8 versus 4.6 months) but not
OS (11.1 versus 9.0 months). As expected, skin toxicity
was greater with the addition of panitumumab. Accord-
ing to the authors, P16-INK4A status could be a prog-
nostic and predictive marker in patients who received
panitumumab and chemotherapy, given that median OS
was longer in the panitumumab group only in patients
with P16-negative tumor status (11.7 vs 8.6 months; HR
0 · 73; p = 0 · 0115). These two trials, although not com-
pletely positive, gave some improvement in treatment
outcomes in a disease with historically poor prognosis
(Figure 3).
Human papillomavirus (HPV) associated with head
and neck cancer generally induces a powerful immune
response. Despite the development of an inflammatory
microenvironment, HPV is able to persist and promote
malignant transformation. The PD-1/PD-L1 immunecheckpoint may play a critical role in the creation of an
immunoprivileged site for viral persistence and for the
subsequent development of cancer. Some authors re-
cently published evidence of the role of the PD-1/PD-L1
pathway in HPV-positive mHNC immune resistance de-
velopment [77]. They demonstrated a strong membran-
ous expression of PD-L1 in the tonsillar crypts, the site
of initial HPV infection, and the role of the PD-1/PD-L1
interaction in creating a privileged site for initial viral in-
fection and subsequent adaptive immune resistance once
tumors are established. This findings suggest a rationale
for therapeutic blockade of this pathway in patients with
HPV-positive mHNC. Clinical trials with nivolumab and
other anti-PD1/PD-L1 drugs are ongoing.
Prostate cancer
Significant progress has been made in the immunotherapy
of prostate cancer in recent years. From a pathogenetic
perspective, prostate cancer should not be considered as a
single disease. The progression from one state to another,
as well as the development of castration-resistant prostate
cancer (CRPC), is likely to be associated with immuno-
logical changes [78]. The development of immunotherapy
strategies, both in hormone-sensitive and in castration-
resistant disease, could be very promising, although defin-
ing clinical responses could be challenging in this setting
of patients with no burden of disease.
In the cell-based vaccines category, sipuleucel-T is
certainly the most extensively studied in prostate cancer.
This vaccine is based upon autologous peripheral-blood
mononuclear cells (PBMCs), activated ex vivo with a
recombinant fusion protein (PA2024). PA2024 is a pros-
tatic acid phosphatase (PAP) fused to an immune-cell
activator, granulocyte-macrophage colony-stimulating fac-
tor (GM-CSF). The IMPACT trial was a double-blind,
placebo-controlled phase III study that involved 512 men
with asymptomatic or minimally symptomatic, castration-
resistant, metastatic prostate cancer [79]. Due to a previ-
ous sipuleucel-T randomized trial that suggested a positive
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disease [80], the IMPACT trial enrolled only men with a
Gleason score ≤7 at diagnosis. Primary endpoint of the
study was reached, with a relative reduction of 22% in
the risk of death in the sipuleucel-T group compared
with the placebo group. This reduction represented a
4.1 month improvement in median OS for the experi-
mental arm. Sipuleucel-T was the first immunotherapy
to reach a statistically significant survival benefit in
prostate cancer. The short duration of treatment and
the favorable toxicity profile were additional benefits.
However, the enrolled cohort in this trial was highly
selected (asymptomatic/minimally symptomatic, Gleason
score ≤7) and does not necessarily reflect the patient
population seen in daily clinical practice. As such, the
results cannot easily be translated.
GVAX-PCa is a vaccine including a mixture of two irra-
diated allogeneic prostate cancer cell lines, LNCaP and
PC-3, which constitutively express GM-CSF. Preclinical
data suggested an additive effect for chemotherapy prop-
erly timed with G-VAX [81]. However, two randomized tri-
als with G-VAX in combination with docetaxel in patients
with CRPC have failed, both with early interruption.
VITAL-1 was a randomized phase III trial with G-VAX
plus docetaxel versus docetaxel alone in patients with
asymptomatic metastatic CRPC which was stopped after
an interim analysis showed inferiority of the experimental
arm. The VITAL-2 trial had the same design, but treatment
was offered to patients with symptomatic disease. The
study was halted at about 1/5 of the enrolment target, due
to an imbalance of deaths between the combined treat-
ment and chemotherapy only arms (n = 67 vs 47) [82].
The role of ipilimumab in prostate cancer is not yet
well established. Ipilimumab failed to meet the pri-
mary endpoint of improving OS in the randomized,
phase III CA184-043 trial that included 799 patients
with post-docetaxel metastatic CRPC [83]. Median OS
was 11.2 months for ipilimumab vs 10 months for pla-
cebo (HR = 0.85, 95%CI = 0.72–1.00, p =0.0530). The
trial met its secondary endpoint of PFS (4 months in
the ipilimumab group vs 3 months in the placebo
group). Pre-specified subset analysis suggested that
ipilimumab improved survival in patients with more
favorable prognostic factors (no visceral metastasis,
lower alkaline phosphatase, and higher haemoglobin
level), a finding that needs to be validated in future
trials [84].
PROSTVAC is a poxviral-based vaccine targeting PSA.
In a randomized phase II trial, PROSTVAC or a control
vector were administered to patients with metastatic
CRPC [85]. This study failed to reach its primary endpoint,
with a median TTP of 3.8 months in the PROSTVAC arm
and 3.7 months in the control arm. Unexpectedly, median
OS greatly favoured PROSTVAC, with a difference of8.5 months (25.1 versus 16.6 months). It has been hypothe-
sized that this difference in results between PFS and OS,
already seen in the sipuleucel-T trial [86], is due to the
long-term effects of immunotherapy, which are not
reflected in earlier endpoints such as TTP. Patients who
died within the first 6–12 months seem to have no benefit
from the vaccine. This should raise issues about evaluating
outcome endpoints in trials with immunotherapy in CRPC.
Immune responses may initially appear as dimensional tu-
moral increase, due to lymphocyte infiltration and inflam-
mation and tumors might progress before immunotherapy
has time to take effect. In randomized trials, immunother-
apy should be tested earlier in patients with CRPC. Follow-
ing treatments should be homogenous between the two
arms, with assessment of time to subsequent progressions.
Bladder and kidney cancer
Although bladder cancer is often a non-muscle invasive
disease at diagnosis, it shows dramatically high local and
distant recurrence rates. Immunotherapy with intravesical
instillation of Bacillus Calmette-Guerin (BCG) remains
the most effective therapy for patients with high-risk,
non-muscle invasive tumors. BCG therapy has significant
limitations though, including AEs and frequent treatment
failures, so new immunotherapeutic strategies are needed.
The immunomodulatory effects following brief expos-
ure to ipilimumab in patients with urothelial carcinoma
of the bladder requiring surgery have been explored in a
clinical trial [87]. Treatment with ipilimumab at 3 mg/kg
or 10 mg/kg was well tolerated and led to an increase of
CD4+ ICOS-high effector cells. Patients were followed
for a median of 20 months and 75% were free of recur-
rence at the time of study publication. This population
of CD4+ ICOS-high cells, which was found to be in-
creased in both tumor tissue and peripheral blood, could
be a biomarker related to clinical outcome in patients
with metastatic disease who received ipilimumab. A
retrospective analysis in patients treated with ipilimu-
mab for metastatic melanoma showed that a sustained
increase in CD4+ ICOS-high cells is correlated with
improved OS.
PD-L1 expression occurs very frequently in urothelial
bladder cancer and may protect cancer cells from
immune-mediated destruction by binding to its receptors
PD-1 and B7.1. MPDL3280A is a human anti-PD-L1
moAb with an engineered Fc-domain that inhibits the
binding of PD-L1 to PD-1 and B7.1. In a phase I study, 68
patients with bladder cancer received MPDL3280A
15 mg/kg q3w for up to 1 year. Preliminary data from this
trial have been presented at ASCO 2014 [88]. More than
2/3 of patients previously received two or more regimens
for advanced disease (97% one platinum-containing ther-
apy). Treatment-related grade 3–4 AEs, mainly asthenia,
occurred only in 4% of patients and there were no irAEs.
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PD-L1-positive patients), including patients with visceral
metastases at baseline. All responding patients had on-
going response at the time of clinical cut-off. Biomarker
analysis revealed an increase of circulating levels of IFN-
gamma, IL-18 and activated CD8+ T-cells, which repre-
sent pharmacodynamic effects. This noteworthy activity of
MPDL3280A in patients with heavily pretreated urothelial
bladder cancer has resulted in it being granted break-
through therapy designation by the FDA.
Renal cell carcinoma (RCC) has long been recognized
as an immunoresponsive tumor, with spontaneous re-
gressions occurring on rare occasions. Treatment with
high dose interleukin-2 (IL-2), although with significant
toxicity, could lead to typically durable CRs in a small
percentage of patients [89]. About 2/3 of clear cell RCC
patients had PD-L1 expression, and most had TILs in
primary RCC. Most patients with high PD-L1 expression
on either tumors or TILs had an advanced disease stage,
worse prognosis and rapid metastatic progression [90].
Patients (n = 43) with metastatic RCC (favorable/inter-
mediate MSKCC score; 80% treated with at least one prior
therapy) were randomized in a phase I study to receive
nivolumab 3 mg/kg + ipilimumab 1 mg/kg (arm N3 + I1)
or nivolumab 1 mg/kg + ipilimumab 3 mg/kg (arm N1 +
I3) q3w for 4 doses, followed by nivolumab 3 mg/kg q2w
until progression or toxicity [91]. Severe grade treatment-
related AEs were most frequently reported in the N1 + I3
arm (60.9% vs 28.6% of patients), mainly GI and hepatic.
No grade 3–4 pneumonitis was observed. ORR was 43%
in the N3 + I1 arm and 48% in the N1 + I3 arm, with about
80% of ongoing responses at the time of data cut-off.
Responses occurred at the time of first tumor assessment
(week 6) in about 50% of responding patients. ORR data
suggest, for the ipilimumab plus nivolumab combination,
greater activity than previously reported with nivolumab
or ipilimumab monotherapy in RCC [17,92].
Breast cancer
Breast cancer has not historically been considered as an
immunogenic tumor when compared with diseases such
as melanoma and RCC, which have used immunother-
apy with some success. Unexpectedly, the ability to pro-
file breast tumors on a molecular level has revealed that
some breast cancers demonstrate a high level of immu-
noregulatory gene activation. Some immune system ef-
fectors or regulating factors have been extensively
studied as prognostic factors or as predictors for good
response to therapy in breast cancer. FOXP3 is a mem-
ber of the forkhead/winged-helix family of transcription
factors involved in regulating immune system develop-
ment and function. This gene plays a crucial role in the
generation of CD4+ CD25+ T-regs. The loss of FOXP3
function leads to a lack of T-regs, resulting in lethalautoaggressive lymphoproliferation, whereas overexpres-
sion of FOXP3 results in severe immunodeficiency [93].
High levels of T-regs have been reported in peripheral
blood, lymph node, tumor specimens, and ascites of pa-
tients with different solid tumors, including breast can-
cer. The intratumoral expression of FOXP3 may be an
indicator that tumor-infiltrating T-regs cells influence
antitumor immunity: for this reason its expression might
be a potential prognostic marker [94]. The expression
patterns of FOXP3 were examined by immunohisto-
chemistry in primary breast cancer specimens from pa-
tients enrolled in the Milan 1 and Milan 3 trials [95].
FOXP3 expression in tumors was associated with worse
OS probability and the risk increased with increasing
FOXP3 immunostaining intensity. FOXP3 was also a
strong prognostic factor for distant metastases-free sur-
vival but not for local recurrence risk. In multivariate
analysis, FOXP3 was an independent prognostic factor,
as were the hazard ratio of FOXP3 expression and
lymph node positivity. These data have identified FOXP3
expression as a new independent prognostic factor in
breast carcinoma, which might help to improve the se-
lection of patients for appropriate therapy.
Many of the current treatments in breast cancer have an
immunogenic effect within the tumor microenvironment.
For example, the neoadjuvant administration of taxanes in
locally advanced disease increases the levels of TILs within
the tumor. In the metastatic setting, docetaxel increases
levels of Th1-associated cytokines (IL-2, IFN-γ) while
decreasing negative inflammatory markers such as tumor-
necrosis factor beta (TNF-β).
In the setting of breast cancer, PD-1-positive T-
lymphocytes have been associated with high histological
grade, ER-negative status, and intense lymphocytic infil-
tration [96]. PD-L1 positivity in breast cancer epithelial
cells and TILs has been associated with similar negative
prognostic factors [97]. Interestingly, a study in an im-
munocompetent mouse model of HER2-positive breast
cancer provided evidence for a therapeutic synergy be-
tween trastuzumab and anti-PD1 MoAb, pointing to-
wards a promising drug combination [98].
Conclusions
There is an ongoing need for new treatment modalities
in patients with advanced solid tumors. Surgery, radi-
ation and cytotoxic/targeted therapies are currently the
mainstay of treatment, but the mortality rate remains
high for most patients with advanced or metastatic dis-
ease. Immuno-oncology is a medical area that focuses
on the development and delivery of new therapies to
generate an effective immune response against cancer.
Improving human immune system responses has long
been thought as a promising approach against solid tu-
mors, although with conflicting results.
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tients with prostate cancer and ipilimumab for patients with
previously-treated unresectable or metastatic melanoma
has renewed great interest in this field, with very promising
initial results in other solid tumors. These agents target the
immune system, so they have the potential to offer a dur-
able cancer control across a variety of tumor types, includ-
ing those that were not historically considered likely to
respond to immune manipulations. Follow-up from phase
II and III trials consistently show a plateau in survival
curves for patients treated with ipilimumab (about 20%)
that is maintained for an extended period, as evidenced by
follow-up of up to 10 years [99]. Immunotherapies generally
have a well-tolerated toxicity profile, with limited long-term
damage upon normal tissues. Ongoing research in this field
will help us to address unmet needs and to understand how
immune-oncology may advance current standards of care
and eventually improve survival outcomes.
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